Immunoreactivity of CD99 in invasive malignant melanoma

Journal of Cutaneous Pathology

Volumn 33, Issue 10, 2006, Pages 663-666

  Wilkerson, Anne E ^a   Glasgow, Meriden A ^b   Hiatt, Kim M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD99 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CELL MEMBRANE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; SPINDLE CELL CARCINOMA;

ANTIGENS, CD; CELL ADHESION MOLECULES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XANTHOMATOSIS;

EID: 33749573655     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00524.x     Document Type: Article

References (16)

1. Herron R, Smith GA. Identification and immunochemical characterization of the human erythrocyte membrane glycoproteins that carry the Xga antigen. Biochem J 1989; 262: 369.
2. Fellinger EJ, Garin-Chesa P, Su SL, et al. Biochemical and genetic characterization of the HBA71 ewing's sarcoma cell surface antigen. Cancer Res 1991; 51: 336.
3. Latron F, Blanchard D, Cartron JP. Immunochemical characterization of the human blood cell membrane glycoprotein recognized by the monoclonal antibody 12e7. Biochem J 1987; 247: 757.
4. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67: 1886.
5. Jung KC, Park WS, Bae YM, et al. Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002; 17: 483.
6. Milanezi F, Pereira EM, Ferreira FV, et al. CD99/MIC-2 surface protein expression in breast carcinomas. Histopathology 2001; 39: 578.
7. Rodriguez I, Ayala E, Caballero C, et al. Solitary fibrous tumor of the thyroid gland: Report of seven cases. Am J Surg Pathol 2001; 25: 1424.
8. Fetsch JF, Laskin WB, Miettinen M. Superficial acral fibromyxoma. A clinicopathologic and immunohistochemical analysis of 37 cases of a distinctive soft tissue tumor with a predilection for the fingers and toes. Hum Pathol 2001; 32: 704.
9. Hahn JH, Kim MK, Choi EY, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997; 159: 2250.
10. Schenkel AR, Mamdouh Z, Chen X, et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143.
11. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol 1999; 193: 17.
12. Sohn HW, Shin YK, Lee IS, et al. CD99 regulates the transport of MHC class I molecules from the golgi complex to the cell surface. J Immunol 2001; 166: 787.
13. Monteagudo C, Calduch L, Navarro S, et al. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol 2002; 117: 126.
14. Kamino H, Tam ST. Immunoperoxidase technique modified by counterstain with azure B as a diagnostic aid in evaluating heavily pigmented melanocytic neoplasms. J Cutan Pathol 1991; 18: 436.
15. Collini P, Mezzelani A, Modena P, et al. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/ewing sarcoma of bone. Am J Surg Pathol 2003; 27: 1161.
16. Gazit R, Rechnitzer H, Achdout H, et al. Recognition of Mycoplasma hyorhinis by cd99-fc molecule. Eur J Immunol 2004; 34: 2032.